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Objective. The purpose of this study was to evaluate microcontainers in vitro and in vivo as an 
innovative oral drug delivery system for the poorly water-soluble drug, furosemide. 
Methods. Microcontainers, with an inner diameter of 223 µm, were fabricated in SU-8 through 
two steps of photolithography. The microcontainers were filled with amorphous sodium salt of 
furosemide (prepared by spray drying). Subsequently, a 10 µm layer of Eudragit® L100 was 
spray coated on the cavity of the drug-filled microcontainers. The release of the drug from the 
microcontainers was evaluated in a biorelevant gastric medium (pH 1.6) and a biorelevant 
intestinal medium at pH 6.5. The intestinal permeability of the amorphous furosemide salt loaded 
into the microcontainers was evaluated using a Caco-2 cell model. Furthermore, drug-filled and 
Eudragit-coated microcontainers were dosed orally to rats and blood samples were taken over 24 
h.   
Results. The release experiments revealed that the Eudragit® layer prevented drug release in the 
gastric medium, while an immediate release of the amorphous furosemide salt was seen in the 
intestinal medium. The Caco-2 cell studies showed a fast permeability of the amorphous 
furosemide salt with no significant differences between the microcontainers (Papp 1.79·10-5 
±0.068·10-5 cm/s, mean±SD, n=11) and powder of amorphous furosemide salt (Papp 1.62·10-5 
±1.04·10-5 cm/s, mean±SD, n=11). The rat study demonstrated that the amorphous furosemide 
salt dosed in microcontainers showed an oral relative bioavailability of 220.2±43.2% 
(mean±SEM, n=6) compared to amorphous furosemide salt filled into capsules and coated with 
Eudragit® L100.   
Conclusions. Microcontainers show considerable potential as a future oral drug delivery system. 
 
